Loading...
Market
Will NTLA-2002 demonstrate over 90% attack reduction in Phase 3 by end of 2026?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Results published by Intellia Therapeutics or in scientific journals
Story
Intellia's NTLA-2002 Shows 81% Attack Reduction in 8 of 11 Patients in Phase 2 HAE Study; FDA Filing Expected in 2026
Oct 24, 2024, 12:18 PM
Intellia Therapeutics has reported promising results from its Phase 2 study of NTLA-2002, an investigational CRISPR gene editing treatment for hereditary angioedema (HAE). In the study, 8 out of 11 patients receiving the mid-level dose showed no attacks during a median follow-up of 9 months post-infusion. The treatment demonstrated an 81% reduction in swelling attacks, indicating a potential for long-term efficacy. The company is planning a larger Phase 3 study with 60 participants and aims to file for FDA approval in 2026. The results position NTLA-2002 as a strong contender in the gene editing landscape, with expectations for it to be one of the first in vivo CRISPR therapies to receive regulatory approval. Other companies, such as Editas Medicine and Beam Therapeutics, are also exploring similar approaches in gene editing for conditions like sickle cell disease and HAE, reflecting a broader shift in the field towards targeted therapies.
View original story
Similar markets
Yes • 50%
No • 50%
Successful with superior efficacy • 25%
Successful with comparable efficacy • 25%
Unsuccessful • 25%
Trial inconclusive • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Yes • 50%
No • 50%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Less than 50% efficacy • 25%
50-69% efficacy • 25%
70-89% efficacy • 25%
90% or higher efficacy • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful reduction in serum TTR levels • 25%
High adverse events lead to study halt • 25%
Modifications required for safety • 25%
Study continuation without major issues • 25%